Biolyst › ACHVACHIEVE LIFE SCIENCES, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: In Vitro & In Vivo Diagnostic Substances.
The next scheduled catalyst is Next quarterly earnings (projected) on November 10, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.
Cash runway is approximately 81.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 30 concluded trials, 90% reached completion rather than being terminated or withdrawn.
Track ACHV alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ACHV in the tracker
Recent history
Date Event Type Phase
October 1, 2026
8-K filed: Leadership change Corporate
—
August 14, 2026
8-K filed: Other event Filing
—
August 11, 2026
Quarterly results filed (8-K) Earnings
—
June 2, 2026
8-K filed: Leadership change Corporate
—
May 12, 2026
Quarterly results filed (8-K) Earnings
—
April 16, 2026
8-K filed: Material agreement, Leadership change, Reg FD disclosure Corporate
—
March 24, 2026
Quarterly results filed (8-K) Earnings
—
November 6, 2025
Quarterly results filed (8-K) Earnings
—
October 7, 2025
8-K filed: Leadership change Corporate
—
September 29, 2025
Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers Trial Milestone
Phase 3
September 11, 2025
8-K filed: Leadership change Corporate
—
August 7, 2025
Quarterly results filed (8-K) Earnings
—
June 27, 2025
8-K filed: Material agreement, Other event Corporate
—
May 13, 2025
Quarterly results filed (8-K) Earnings
—
September 21, 2023
Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers Trial Milestone
Phase 1
September 4, 2023
Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose Trial Milestone
Phase 1
March 21, 2023
A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers Trial Milestone
Phase 3
February 28, 2023
A Study of Cytisinicline for Vaping Cessation in Adult Smokers Trial Milestone
Phase 2
December 23, 2022
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers Trial Milestone
Phase 1
December 23, 2021
A Study of Cytisinicline for Smoking Cessation in Adult Smokers Trial Milestone
Phase 3
September 12, 2019
A Single Dose-escalation Study of Cytisine in Adult Smokers Trial Milestone
Phase 1
April 23, 2019
Trial of Cytisine in Adult Smokers Trial Milestone
Phase 2
October 5, 2018
A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers Trial Milestone
Phase 1/Phase 2
June 10, 2018
A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation Trial Milestone
Phase 1
August 26, 2017
A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine Trial Milestone
Phase 1
November 17, 2016
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Trial Milestone
Phase 3
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.